Skip to main page content
Access keys NCBI首页 MyNCBI Homepage Main Content 主要导航
Randomized Controlled Trial
。 2021年7月29日; 58（1）：2001798。
doi: 10.1183/13993003.01798-2020. 印刷2021年7月。

辛伐他汀可以减少COPD加重吗？随机双盲对照研究

彼得·申克（Peter Schenk）1，，，， 亚历山大·斯皮尔（Alexander O Spiel）23，，，， FelixHüttinger4，，，， Micheline Gmeiner4，，，， Josefine Fugger5，，，， Martina Pichler4，，，， Gernot Pichler4，，，， Susanne Schmeikal6，，，， Wolfgang Janistyn7，，，， StefanSchügerl8，，，， Constantin Sajdik4，，，， Harald Herkner2
Affiliations
Randomized Controlled Trial

辛伐他汀可以减少COPD加重吗？随机双盲对照研究

彼得·申克（Peter Schenk）等。 Eur Respir J。 。

Abstract

Background:多项研究表明,他汀类药物有beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation.

Methods:我们以40 mg的每日剂量进行了辛伐他汀的随机双盲安慰剂对照单中心试验versusplacebo in patients with Global Initiative for Chronic Obstructive Lung Disease criteria grades 2-4 at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12 months and the main outcome parameter was time to first exacerbation.

Results:Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo: median 341versus140天（对数秩检验p <0.001）。辛伐他汀组首次加重风险的危险比为0.51（95％CI 0.34-0.75; p = 0.001）。辛伐他汀的加重率显着降低：103（41％）versus147（59％）（p = 0.003）。在辛伐他汀组中，年度加重率为每年患者年的每年1.45个事件，安慰剂组的每年患者年为1.9个事件（发病率比0.77，95％CI 0.60-0.99）。我们发现对生活质量，肺功能，6分钟步行测试和高敏性C反应蛋白没有影响。与安慰剂组相比，更多的患者在辛伐他汀组辍学（39例versus29).

Conclusion:In our single-centre RCT, simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.

Conflict of interest statement

Conflict of interest: P. Schenk reports a scientific research grant for performing the study by Life Science 2010, NÖ Forschungs- und Bildungsges m.b.H., Austria. Conflict of interest: A.O. Spiel has nothing to disclose. Conflict of interest: F. Hüttinger has nothing to disclose. Conflict of interest: M. Gmeiner has nothing to disclose. Conflict of interest: J. Fugger has nothing to disclose. Conflict of interest: M. Pichler has nothing to disclose. Conflict of interest: G. Pichler has nothing to disclose. Conflict of interest: S. Schmeikal has nothing to disclose. Conflict of interest: W. Janistyn has nothing to disclose. Conflict of interest: S. Schügerl has nothing to disclose. Conflict of interest: C. Sajdik has nothing to disclose. Conflict of interest: H. Herkner has nothing to disclose.

评论

类似的文章

  • Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.
    Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, Make B, Marchetti N, Martinez FJ, Niewoehner DE, Scanlon PD, Sciurba FC, Scharf SM, Sin DD, Voelker H, Washko GR, Woodruff PG, Lazarus SC; COPD Clinical Research Network; Canadian Institutes of Health Research. Criner GJ, et al. N Engl J Med。2014Jun 5;370(23):2201-10. doi: 10.1056/NEJMoa1403086. Epub 2014 May 18. N Engl J Med。2014。 PMID:24836125 免费PMC文章。 临床试验。
  • 低剂量的口服茶碱与慢性阻塞性肺部疾病和高风险患者的吸入皮质类固醇相结合：A RCT。
    Devereux G，Cotton S，Fielding S，McMeekin N，Barnes PJ，Briggs A，Burns G，Chaudhuri R，Chrystyn H，Davies L，Soyza A，Gompertz S，Gompertz S，Haughney J，Innes K，Innes K，Kaniewska J，Lee A，Morice A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A A，Morice A，Morice A，，Norrie J，Sullivan A，Wilson A，Price D. Devereux G, et al. Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370. Health Technol Assess. 2019. PMID:31343402 免费PMC文章。 临床试验。
  • COPD的门诊治疗的急性加重：一项随机双盲安慰剂对照试验。
    Van Velzen P，Ter Riet G，Bresser P，Baars JJ，Van Den Berg BTJ，Van Den Berg JWK，Brinkman P，Dagelet JWF，Daniels JMA，Groeneveld-Tjiong Drgl，Jonkers RE，Jonkers RE，Van Kan C，Krouwels FH，Pool ke k，KROUWELS FH，POOL KAUWELS FH，POOL KAUWELS FH，POOL KAUWELS RE，Rudolphus A，Sterk PJ，Prins JM。 van Velzen P等。 柳叶刀呼吸医学。2017Jun;5(6):492-499. doi: 10.1016/S2213-2600(17)30165-0. Epub 2017 May 5. 柳叶刀呼吸医学。2017。 PMID:28483402 临床试验。
  • 他汀类药物与安慰剂，适合患有慢性阻塞性肺部疾病的人。
    Walsh A，Perrem L，Khashan AS，Henry MT，Ni Chroinin M. Walsh A, et al. Cochrane数据库Syst Rev. 2019年7月31日； 7（7）：CD011959。doi：10.1002/14651858.cd011959.pub2。在线印刷。 Cochrane Database Syst Rev. 2019. PMID:31425628 免费PMC文章。 Review.
  • tiototium v​​ and安慰剂用于慢性阻塞性肺部疾病。
    Karner C, Chong J, Poole P. Karner C等。 Cochrane Database Syst Rev. 2014 Jul 21;(7):CD009285. doi: 10.1002/14651858.CD009285.pub3. Cochrane Database Syst Rev. 2014. PMID:25046211 Review.
查看所有类似的文章

Cited by1文章

Publication types

网格条款

Substances

关联的数据

链接 - 更多资源